Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study von Takashima, Atsuo, García-Alfonso, Pilar, Manneh, Raimundo, Beşen, Ali Ayberk, Hong, Yong Sang, Cuyle, Pieter-Jan, Yanez, Patricio, Burge, Matthew, Yoshino, Takayuki, Kim, Tae Won, Cui, Karen, Li, Chenxiang, Jain, Rishi, Adelberg, David, Taieb, Julien

Volltext

Immunotherapy in Hispanic patients with advanced non-small cell lung cancer: A real-world data von Lujan, Mauricio, Lema, Mauricio, Preciado, Beatriz, Lema, Camila, Egurrola, Jorge, Cardona Zorrilla, Andres Felipe, Gonzalez, Diego Mauricio, Mantilla, William Armando, Pino, Luis, Rojas, Gustavo, Gomez-Abreo, Diego Andres, Munevar, Isabel, Manneh, Raimundo, Manneh Kopp, Ray, Lobaton, Jose F., Calle, Esteban, Borras, Mariana, Triana, Ivan Camilo, Pineda, Mateo, Moran Ortio, Diego

Volltext

Real-world evidence of nivolumab for non-small-cell lung cancer in a developing country von Luján, Mauricio, Lema, Mauricio, Preciado, Beatriz, Lema, Camila, Egurrola, Jorge, Cardona, Andrés, González, Diego, Mantilla, William, Pino, Luis, Rojas, Gustavo, Gómez, Diego, Munevar, Isabel, Manneh, Raimundo, Manneh, Ray, Lobatón, José, Calle, Esteban, Borras, Mariana, Triana, Iván, Londoño, Paula, Aruachán, Sandra, Pineda, Mateo, Morán, Diego

Volltext